Garattini S, Forloni G L, Tirelli S, Ladinsky H, Consolo S
Psychopharmacology (Berl). 1984;82(3):210-4. doi: 10.1007/BF00427775.
Minaprine, a novel psychotropic drug with antidepressant, anticataleptic and antiaggressive properties, produced an increase in rat brain regional acetylcholine content at a subconvulsant dose of 30 mg/kg IP. The greatest increase (60%) was produced in the striatum, whereas an increase of about 35% was obtained in the hippocampus and the rest of the cortex. A small but significant increase of 14% was also found in the midbrain-hindbrain region. Minaprine decreased choline content only in the striatum. No tolerance to acute challenge was observed after 10-day chronic treatment. In vitro, the drug had no effect on striatal choline acetyltransferase activity up to a concentration of 160 microM and only weakly displaced (3H) dexetimide from its specific muscarinic receptor binding sites in striatum (IC50, 2 X 10(-4) M). After in vivo administration the drug did not affect sodium-dependent high affinity choline uptake by a hippocampal homogenate. On the other hand, the drug inhibited both striatal and hippocampal acetylcholinesterase activity at high (40-160 microM) concentrations in vitro. In vivo the drug produced a brief (5 min), small (18%) decrease in the enzymic activity which corresponded in time to the peak drug level attained in the brain, but was not concomitant with a change in striatal acetylcholine content. By contrast, the increase in striatal acetylcholine appeared after 30 min when there was no longer inhibition of acetylcholinesterase activity and when the level of minaprine in brain was reduced by 78%. Blockade of dopamine receptors by pimozide pretreatment partially prevented the increase in striatal acetylcholine produced by minaprine, whereas interference with cholinergic or serontonergic neurotransmission was without effect.(ABSTRACT TRUNCATED AT 250 WORDS)
米那普明是一种具有抗抑郁、抗僵住症和抗攻击特性的新型精神药物,腹腔注射30mg/kg的亚惊厥剂量可使大鼠脑区乙酰胆碱含量增加。纹状体中增加最为显著(60%),而海马体和其余皮质区增加约35%。中脑-后脑区域也有14%的小幅但显著增加。米那普明仅使纹状体中的胆碱含量降低。10天的慢性治疗后未观察到对急性刺激的耐受性。在体外,该药物浓度高达160μM时对纹状体胆碱乙酰转移酶活性无影响,且仅微弱地将(3H)右旋苯乙哌啶从其在纹状体中的特异性毒蕈碱受体结合位点上置换下来(IC50为2×10(-4)M)。体内给药后,该药物不影响海马体匀浆对钠依赖性高亲和力胆碱的摄取。另一方面,该药物在体外高浓度(40 - 160μM)时可抑制纹状体和海马体的乙酰胆碱酯酶活性。在体内,该药物使酶活性短暂(5分钟)、小幅(18%)降低,这与脑中达到的药物峰值水平在时间上相对应,但与纹状体乙酰胆碱含量的变化无关。相比之下,纹状体乙酰胆碱的增加出现在30分钟后,此时乙酰胆碱酯酶活性不再受到抑制,且脑中米那普明水平降低了78%。用匹莫齐特预处理阻断多巴胺受体会部分阻止米那普明引起的纹状体乙酰胆碱增加,而干扰胆碱能或5-羟色胺能神经传递则无作用。(摘要截短于250字)